Adaptimmune Therapeutics plc
ADAP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$70,814 | -$113,871 | -$165,456 | -$158,090 |
| Dep. & Amort. | $11,225 | $9,453 | $6,075 | $6,567 |
| Deferred Tax | $0 | $0 | $0 | $5,816 |
| Stock-Based Comp. | $12,051 | $11,773 | $18,240 | $20,629 |
| Change in WC | -$36,995 | -$24,952 | -$1,531 | $134,618 |
| Other Non-Cash | $11,327 | -$23,670 | $903 | $6,989 |
| Operating Cash Flow | -$73,206 | -$140,880 | -$141,769 | $10,729 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$2,721 | -$4,681 | -$29,740 | -$8,574 |
| Net Acquisitions | $0 | $45,264 | $77,857 | $207 |
| Inv. Purchases | -$100,418 | -$75,953 | -$48,117 | -$139,745 |
| Inv. Sales/Matur. | $44,057 | $210,983 | $166,891 | $224,316 |
| Other Inv. Act. | $130 | $1,128 | -$77,857 | -$207 |
| Investing Cash Flow | -$58,952 | $176,538 | $89,137 | $75,800 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $49,500 | $0 | $0 | $0 |
| Stock Issued | $29,172 | $624 | $12,817 | $2,529 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $77 | $256 | $50 | $759 |
| Financing Cash Flow | $78,749 | $880 | $12,867 | $3,288 |
| Forex Effect | -$402 | $877 | -$2,299 | $365 |
| Net Chg. in Cash | -$53,811 | $37,415 | -$42,064 | $90,182 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $147,017 | $109,602 | $151,666 | $61,484 |
| End Cash | $93,206 | $147,017 | $109,602 | $151,666 |
| Free Cash Flow | -$75,926 | -$145,760 | -$171,509 | $1,948 |